title: Depot-Based Delivery Systems for Pro-Angiogenic Peptides: A Review.
abstract: Insufficient vascularization currently limits the size and complexity for all tissue engineering approaches. Additionally, increasing or re-initiating blood flow is the first step toward restoration of ischemic tissue homeostasis. However, no FDA-approved pro-angiogenic treatments exist, despite the many pre-clinical approaches that have been developed. The relatively small size of peptides gives advantages over protein-based treatments, specifically with respect to synthesis and stability. While many pro-angiogenic peptides have been identified and shown promising results in vitro and in vivo, the majority of biomaterials developed for pro-angiogenic drug delivery focus on protein delivery. This narrow focus limits pro-angiogenic therapeutics as peptides, similar to proteins, suffer from poor pharmacokinetics in vivo, necessitating the development of controlled release systems. This review discusses pro-angiogenic peptides and the biomaterials delivery systems that have been developed, or that could easily be adapted for peptide delivery, with a particular focus on depot-based delivery systems.
authors.affiliation: Department of Biomedical Engineering, University of Rochester , Rochester, NY , USA.
authors.forename: Amy H
authors.initials: AH
authors.lastname: Van Hove
authors.affiliation: Department of Biomedical Engineering, University of Rochester , Rochester, NY , USA ; Department of Chemical Engineering, University of Rochester , Rochester, NY , USA ; Department of Biomedical Genetics, University of Rochester Medical Center , Rochester, NY , USA ; Department of Orthopaedics, Center for Musculoskeletal Research, University of Rochester Medical Center , Rochester, NY , USA.
authors.forename: Danielle S W
authors.initials: DS
authors.lastname: Benoit
keywords: angiogenesis; biomaterials; controlled release; depot-based; drug delivery; hydrogels; review